On March 22, 2016 CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, reported that it will present two posters with new preclinical data based on its proprietary LADR technology at the upcoming 2016 American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, April 16-20, 2016, being held at the Ernest N. Morial Convention Center in New Orleans, Louisiana (Press release, CytRx, MAR 22, 2016, View Source [SID:1234509819]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Highlights include data on DK049, CytRx’s next albumin-binding drug conjugate nominated for clinical development, which demonstrated superior anti-tumor efficacy compared to gemcitabine in human patient-derived tumor xenograft models of non-small cell lung cancer, ovarian cancer and pancreatic cancer. DK049 decreases the clearance and drug resistance mechanisms that limit the effectiveness of gemcitabine, one of the most commonly used chemotherapy drugs. As a result, DK049’s superior anti-tumor efficacy was achieved using a significantly reduced dose compared to gemcitabine. CytRx plans to commence clinical trials with DK049 in the second half of this year.

CytRx’s second poster details the broad capabilities of the Company’s LADRTM (Linker Activated Drug Release) technology platform. A key advantage is a suite of versatile linkers with the ability to control the release profile of potent cytotoxic agents between 1-50 hours to create personalized therapies for specific cancers. DK049 and the LADRTM technology platform were created in-house at CytRx’s drug discovery lab in Freiburg, Germany.

"The posters that will be presented highlight for the first time the uniquely tunable nature of the LADRTM platform and its ability to create novel drug candidates, like DK049, with superior anti-tumor activity," said Felix Kratz, PhD, CytRx’s Vice President of Drug Discovery.

The following CytRx abstracts have been selected for AACR (Free AACR Whitepaper) poster presentations:

Title: DK049, a novel acid-sensitive prodrug of gemcitabine: design, in vitro properties and in vivo efficacy
Date/Time: Monday, April 18, 1:00pm – 5:00pm CDT
Session Title: Drug Delivery; Poster Section 15, Abstract #2061
Title: LADR: A novel linker activated drug release technology for drug delivery
Date/Time: Wednesday, April 20, 8:00am – 12:00pm CDT
Session Title: Drug Design; Poster Section 21, Abstract #4858